Efficacy and Safety of Soybean Germ Extract on Decrease of Body Fat

Overview

This study was conducted to investigate the effects of daily supplementation of Soybean germ extract on decrease of body fat

Full Title of Study: “A 12-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Soybean Germ Extract on Decrease of Body Fat”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: February 28, 2020

Detailed Description

This study was a 12 weeks, randomized, double-blind, placebo-controlled human trial. 80 subjects were randomly divided into Soybean germ extract 1,600 mg or placebo group. The investigators measured Body Fat Mass, Percent Body Fat, Fat Free Mass, weight, and body mass index, etc.

Interventions

  • Dietary Supplement: Soybean Germ Extract
    • Soybean Germ Extract 1,600 mg/day for 12 weeks.
  • Dietary Supplement: Placebo
    • Placebo 1,600 mg/day for 12 weeks.

Arms, Groups and Cohorts

  • Experimental: Soybean Germ Extract
    • Soybean Germ Extract 1,600 mg/day for 12 weeks.
  • Placebo Comparator: Placebo
    • Placebo 1,600 mg/day for 12 weeks.

Clinical Trial Outcome Measures

Primary Measures

  • Changes of body fat mass
    • Time Frame: Baseline and 12 week
    • Body fat mass was measured in study baseline and 12 week

Secondary Measures

  • Changes of percent body fat
    • Time Frame: Baseline and 12 week
    • Measurement is made using dual energy X-ray absorptiometry (DEXA / Hologic Discovery, USA). Left arm, right arm, left leg, right leg, trunk, total will be report percent body fat in %.
  • Changes of fat free mass
    • Time Frame: Baseline and 12 week
    • Measurement is made using dual energy X-ray absorptiometry (DEXA / Hologic Discovery, USA). Left arm, right arm, left leg, right leg, trunk, total will be report fat free mass in g.
  • Changes of Anthropometric indicate: body weight
    • Time Frame: Screening, baseline and 12 week
    • Anthropometric indices were measured in study screening, baseline and 12 week. Body weight in kg.
  • Changes of Anthropometric indicate: body mass index
    • Time Frame: Screening, baseline and 12 week
    • Anthropometric indices were measured in study screening, baseline and 12 week. Weight/height^2 will be report body mass index in kg/m^2.
  • Changes of Anthropometric indices: waist circumference, hip circumference
    • Time Frame: Screening, baseline and 12 week
    • Anthropometric indices were measured in study screening, baseline and 12 week. Waist circumference, hip circumference in cm.
  • Changes of Anthropometric indicate: waist -hip circumference ratio
    • Time Frame: Screening, baseline and 12 week
    • Anthropometric indices were measured in study screening, baseline and 12 week. Waist circumference/hip circumference will be report waist -hip circumference ratio.
  • Changes of lipid metabolism indicators: Total cholesterol, Triglyceride, LDL-cholesterol, HDL-cholesterol
    • Time Frame: Baseline and 12 week
    • Lipid metabolism indicators(mg/dL) were measured in study baseline and 12 week.
  • Changes of obesity-related hormones indicators: Adiponectin, Leptin
    • Time Frame: Baseline and 12 week
    • obesity-related hormones indicators were measured in study baseline and 12 week
  • Changes of energy expenditure Indicators: Uncoupling protein-1(UCP-1), Peroxisome proliferator-activated receptor gamma coactivator-1 α(PGC-1 α)
    • Time Frame: Baseline and 12 week
    • energy expenditure Indicators were measured in study baseline and 12 week

Participating in This Clinical Trial

Inclusion Criteria

  • age between 19 and 65 years – BMI 25~29.9 kg/m^2 – After fully hearing and fully understanding this clinical trials, those who agree to voluntarily decide to participate and to comply with the notice Exclusion Criteria:

  • Those who lost more than 10% of their weight within 3 months before the screening – Those who take a product(body fat improvement health functional foods, birth control pills, steroids, female hormone) that affects your weight within 4 weeks prior to the screening – Those with clinically significant severe cardiovascular, endocrine, immune, respiratory, liver, biliary, renal and urinary tract, neuropsychiatry, musculoskeletal, inflammatory and hematologic and gastrointestinal disorders – Diabetic patients taking oral hypoglycemic agents or insulin (based on screening subjects) – A person with a history of clinically significant hypersensitivity to soybeans – Those who have received antipsychotic medication within 2 months before screening – Anyone with substance abuse or suspicion – Those who participated in other clinical trials within 3 months before screening – Systolic Blood Pressure(SBP) 180 mmHg, Diastolic Blood Pressure(DBP) 110 mmHg or more – Menopausal woman – Laboratory test by show the following results – Aspartate Transaminase(AST), Alanine Transaminase(ALT) > Reference range 3 times upper limit – Serum Creatinine > 2.0 mg/dL – Pregnancy or breast feeding – Those who doesn't accept the implementation of appropriate contraception of a childbearing woman – Principal Investigator judged inappropriate for participation in study because of Laboratory test result, etc.

Gender Eligibility: All

Minimum Age: 19 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Chonbuk National University Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Soo-Wan Chae, Principal Investigator, Clinical Trial Center for Functional Foods – Chonbuk National University Hospital
  • Overall Contact(s)
    • Soo Wan Chae, Ph.D., M.D., 82-63-259-3040, soowan@jbnu.ac.kr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.